USANA Q3 net sales $213M, EPS $0.59; narrows FY 2023 guidance

USANA HEALTH SCIENCES INC

2023-Q3 EPS reported $2.43 revenue$699,927,000

Q3 net sales $213M (-9% YoY); diluted EPS $0.59 (-24% YoY).
Active customers 464,000 (-2% YoY); Asia Pacific region sales $170M (-7% YoY).
Greater China net sales $107M (-3% YoY, +2% constant currency); active customers +8%.
FY 2023 outlook narrowed: net sales $900-$920M, EPS $2.80-$3.05 (prev. $900-$950M, $2.65-$3.30).
Repurchased 180K shares for $12M; ended quarter debt-free with $307M cash.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

USANA HEALTH SCIENCES INC reported the third quarter ended September 30, 2023 results: revenue $213 million, EPS $0.59.

Period: the third quarter ended September 30, 2023
Revenue: $213 million
EPS: $0.59
Result: reported results

Exact text from the filing

Third quarter net sales were $213 million versus $233 million during Q3 2022. Third quarter diluted EPS was $0.59 as compared with $0.78 during Q3 2022. Company narrows fiscal year 2023 net sales and diluted EPS outlook to $900 million to $920 million and $2.80 to $3.05, respectively (previously $900 million to $950 million and $2.65 to $3.30).

View on SEC.gov

Browse all earnings releases →

USANA HEALTH SCIENCES INC filing history →

Source: SEC EDGAR

accession 0001157523-23-001529

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.